Abstracts tagged "autoantibodies"

Abstract Number: 1776 • 2012 ACR/ARHP Annual Meeting
Anti-SSA/Ro Mediated Injury to the Endothelium Via Urokinase Plasminogen Activator Receptor/Tgfbeta Activation: Implications in the Pathogenesis of Congenital Heart Block
Paraskevi Briasouli¹, Mark Halushka², Jill P. Buyon³ and Robert M. Clancy⁴, ¹Rheumatology, New York University Medical Center, New York, NY, ²Division of Cardiovascular Pathology, John Hopkins Pathology, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, ⁴Medicine, New York University School of Medicine, New York, NY
Background/Purpose: One mechanism by which anti-Ro antibodies are linked to the pathogenesis of (cardiac-NL) neonatal lupus is the increased urokinase plasminogen activator (uPA)/urokinase-type plasminogen activator receptor…
Abstract Number: 977 • 2012 ACR/ARHP Annual Meeting
14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Walter P. Maksymowych¹, Vivian P. Bykerk², Désirée van der Heijde³, R. Landewe⁴ and Anthony Marotta⁵, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: 14-3-3 eta is normally an intracellular protein and only in the disease state is it released into the extracellular space. We have previously presented…
Abstract Number: 277 • 2012 ACR/ARHP Annual Meeting
Dyslipidemia in Juvenile Dermatomyositis: The Role of Disease Activity
Katia T. Kozu¹, Clovis Artur Silva², Eloisa Bonfa³, Adriana M. Sallum⁴, Rosa M.R. Pereira⁵, Vilma S. Viana⁶, Eduardo F. Borba⁷ and Lucia M. A. Campos⁴, ¹Pediatric Rheumatology Unit, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Paediatric Rheumatology International Trials Organization (PRINTO), Istituto Giannina Gaslini, Genova, Italy, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Pediatric Rheumatology Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁵Rheumatology, University of São Paulo, São Paulo, Brazil, ⁶Rheumatology Division, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ⁷Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil
Background/Purpose: Dyslipidemia has been infrequently investigated in pediatric population with autoimmune rheumatic diseases. However, lipid abnormalities in these diseases may occur due to multiple risk…
Abstract Number: 2574 • 2012 ACR/ARHP Annual Meeting
Smoking, Autoantibodies and Vascular Events in Systemic Lupus Erythematosus
Johanna Gustafsson¹, Iva Gunnarsson¹, Susanne Pettersson¹, Agneta Zickert¹, Anna Vikerfors², Erik Hellbacher², Sonia Möller¹, Kerstin Elvin³, Henrik Källberg⁴, Julia F. Simard⁵ and Elisabet Svenungsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ³Department of Clinical Immunology and Transfusion Medicine,, Karolinska Institutet, Stockholm, Sweden, ⁴Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁵Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Smoking is a risk factor for several autoimmune diseases including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Smoking is also a major risk…
Abstract Number: 1747 • 2012 ACR/ARHP Annual Meeting
Gemin5 Is a New Target of Autoantibodies That Are Produced in Tight Connection with Antibodies to Snrnps and Survival of Motor Neuron (SMN) Complex
Jason YF Chan¹, Yi Li¹, Angela Ceribelli², Eric S. Sobel³, Westley H. Reeves⁴, Edward K.L. Chan² and Minoru Satoh¹, ¹Medicine, University of Florida, Gainesville, FL, ²Oral Biology, University of Florida, Gainesville, FL, ³Medicine/Div of Rheumatology, University of Florida, Gainesville, FL, ⁴Rheumatology & Clinical Imm, University of Florida, Gainesville, FL
Background/Purpose: Most targets of autoantibodies in systemic rheumatic diseases are multiprotein-nucleic acids complex. Small nuclear ribonucleoproteins (snRNPs, Sm and U1RNP), key functional components of the…
Abstract Number: 885 • 2012 ACR/ARHP Annual Meeting
Interferon α and Self-Organized Criticality Theory
Shunichi Shiozawa¹, Yumi Miyazaki² and Ken Tsumiyama³, ¹Department of Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ²Kyushu University Beppu Hospital/ Kobe University Graduate School of Health Sciences, Beppu/ Kobe, Japan, ³Department of Rheumatology, Kyushu University Beppu Hospital, Beppu, Japan
Background/Purpose: One of the biggest obstacle we face in elucidating the pathogenesis of autoimmunity today is the mechanism how autoreactive lymphocyte clones could survive or…
Abstract Number: 229 • 2012 ACR/ARHP Annual Meeting
Clinical Differences Between Adult and Juvenile Dermatomyositis Associated with Anti-NXP2 Autoantibodies
Sarah Tansley¹, Zoe Betteridge¹, Harsha Gunawardena², Lucy R. Wedderburn³, Hector Chinoy⁴, Robert G. Cooper⁵, Jiri Vencovsky⁶, Lenka Plestilova⁷, Ingrid E. Lundberg⁸, Katalin Danko⁹, Melinda Vincze¹⁰, Neil McHugh¹¹, UK JDRG¹² and EuMyoNet¹³, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Rheumatology, North Bristol NHS Trust, Bristol, United Kingdom, ³Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁴Rheumatology, The University of Manchester, Manchester, United Kingdom, ⁵Rheumatic Diseaes Center, Salford Royal Foundation Trust, Salford, United Kingdom, ⁶Institute of Rheumatology, Prague, Czech Republic, ⁷Institute of Rheumatology, Prague 2, Czech Republic, ⁸Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, ⁹University of Debrecen, University of Debrecen, Debrecan, Hungary, ¹⁰University of Debrecen, University of Debrecen, Debrecen, Hungary, Debrecan, Hungary, ¹¹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹²Institute of Child Health, London, United Kingdom, ¹³Rheumatology Unit, Stockholm, Sweden
Background/Purpose: Myositis specific antibodies (MSA) can divide dermatomyositis patients into distinct clinical subsets and help predict the risk of disease complications such as interstitial lung…
Abstract Number: 2575 • 2012 ACR/ARHP Annual Meeting
Inhibition of Pathogenic Autoantibodies by Accelerating the Exit of Germinal Center B Cells Via Manipulation of Regulator of G-Protein Signaling
John D. Mountz¹, John H. Wang², James S. New³, PingAr Yang⁴, Qi Wu⁴, Bao Luo⁵, Jun Li⁶, Kirk M. Druey⁷ and Hui-Chen Hsu⁴, ¹Dept of Med/Rheumatology Div, Univ of Alabama at Birmingham and Birmingham VA Medical Center, Birmingham, AL, ²Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA, ³Grad Sch - Biomed Sciences, University of Alabama at Birmingham, Birmingham, AL, ⁴Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁷Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, Bethesda, MD
Background/Purpose: Regulator of G-protein Signaling (RGS) plays a key role in inhibiting chemokine signaling by desensitizing G-protein coupled receptor signals. RGS13 and RGS16 are two…
Abstract Number: 1748 • 2012 ACR/ARHP Annual Meeting
Antibody Secreting Cells Arising After Vaccination of Lupus Patients May Produce High Affinity Autoantibodies
Kenneth Smith¹, Jennifer Muther¹, Angie Duke¹, Emily McKee¹, Alina Lorant¹, Patrick C. Wilson² and Judith A. James³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Rheumatology and Knapp center for Lupus and Immunology Research, University of Chicago, Chicago, IL, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Vaccinating SLE patients with influenza and pneumococcal vaccines is generally considered safe and effective. However, conflicting reports regarding the impact of vaccination on autoantibody…
Abstract Number: 889 • 2012 ACR/ARHP Annual Meeting
Modeling Environmental and Genetic Determinants to Identify the Association of Risk Genes in Anti-Ro60-Mediated Injury: Relaxin Receptor I and Tumor Necrosis Factor
Joanne H. Reed¹, Paula S. Ramos², Jiri Zavadil³, Jill P. Buyon⁴ and Robert M. Clancy¹, ¹Medicine, New York University School of Medicine, New York, NY, ²Department of Medicine, Medical University of South Carolina, Charleston, SC, ³Pathology and Center for Health Informatics and Bioinformtics, New York University School of Medicine, New York, NY, ⁴Department of Medicine, New York University School of Medicine, New York, NY
Background/Purpose: Fetuses exposed to maternal anti-Ro60 antibodies can develop cardiac conduction abnormalities and life threatening cardiomyopathy; manifestations of neonatal lupus (NL). Recent data support an injury…
Abstract Number: 233 • 2012 ACR/ARHP Annual Meeting
IFN Signature Is Associated with Autoantibody Profiles in Patients with Idiopathic Inflammatory Myopathies
Saskia Vosslamber¹, Louise Ekholm², Anna Tjarnlund³, Clio P. Mavragani⁴, Lenka Plestilova⁵, Martin Klein⁶, Mary K. Crow⁷, Peter J. Charles⁸, Leonid Padyukov⁹, Jiri Vencovsky⁵, Ingrid E. Lundberg¹⁰ and Cornelis L. Verweij¹, ¹Pathology, VU University Medical Center, Amsterdam, Netherlands, ²Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ³Pathology, Rheumatology Unit, Department of Medicine, Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Experimental Physiology, School of Medicine, University of Athens, Athens, Greece, Athens, Greece, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Institute of Rheumatology, Prague, Prague, Czech Republic, ⁷Department of Medicine, Hospital for Special Surgery, New York, NY, ⁸Oxford University, Kennedy Institute of Rheumatology, Oxford, United Kingdom, ⁹Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ¹⁰Rheumatology Unit, Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Sweden, Stockholm, Sweden
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases characterized by the presence of autoantibodies, proximal muscle weakness and muscle inflammation. Recent studies showed an…
Abstract Number: 2578 • 2012 ACR/ARHP Annual Meeting
Monoclonal IgG Antibodies (ACPAs) From Synovial Fluid B Cells of Rheumatoid Arthritis Patients – Antigen-Driven Affinity Maturation and Cross Reactivity
Khaled Amara¹, Johanna Steen², Fiona Murray², Henner Morbach³, Blanca Fernandez-Rodriguez⁴, Vijay Balasingh², Marianne Engström², Omri Snir², Lena Israelsson⁵, Anca Catrina², Hedda Wardemann⁶, Davide Corti⁴, Eric Meffre Sr.³, Lars Klareskog⁷ and Vivianne Malmström⁸, ¹Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, ²Department of Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ³Department of Immunobiology, Yale University School of Medicine, New Haven, CT, ⁴Institute for Research in Biomedicine, Bellinzona, Switzerland, ⁵Medicine, Rheumatology unit, Karolinska University Hospital, Karolinska Institute, Stockholm, Sweden, ⁶Max Planck Research Group Molecular Immunology, Max Planck Institute for Infection Biology, Berlin, Germany, ⁷Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁸Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Antibodies targeting citrullinated proteins (ACPA) are commonly found in patients with Rheumatoid Arthritis (RA), strongly associate with distinct HLA-DR alleles and predict a more…
Abstract Number: 1753 • 2012 ACR/ARHP Annual Meeting
A Rheumatoid Factor Paradox: Inhibition of Rituximab-Induced Complement Dependent Cytotoxicity of B Cells
Jonathan D. Jones¹, Irene Shyu², Marianna M. Newkirk³ and William F. C. Rigby², ¹Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Rheumatology, Dartmouth-Hitchcock Med Ctr, Lebanon, NH, ³Medicine, McGill University Health Centr, Montreal, QC, Canada
Background/Purpose: Rheumatoid factor (RF) is an autoantibody directed against the Fc portion of IgG antibodies. It is found in ~80% of patients with rheumatoid…
Abstract Number: 854 • 2012 ACR/ARHP Annual Meeting
Anti-EIF2B: A Novel Interstitial Lung Disease Associated Autoantibody in Patients with Systemic Sclerosis
Zoe Betteridge¹, Felix Woodhead², Christopher Bunn³, Christopher D. Denton⁴, David J. Abraham⁵, Sujal Desai⁶, Roland du Bois⁷, Athol U. Wells⁸ and Neil McHugh⁹, ¹Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²Respiratory, University Hospitals Coventry and Warwickshire, Coventry, United Kingdom, ³Immunology, Royal Free Hospital, London, United Kingdom, ⁴Department of Rheumatology, Royal Free and University College Medical School, London, England, ⁵UCL Medical School, London, United Kingdom, ⁶Radiology, Kings College Hosptial, London, United Kingdom, ⁷National Jewish Health, Denver, ⁸Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁹Department of Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Autoantibodies occur in 75-95% of Systemic Sclerosis (SSc) patients. Studies have shown that the presence of particular SSc-specific autoantibodies (anti-centromere, anti-topoisomerase-1, anti-RNA polymerase III,…
Abstract Number: 176 • 2012 ACR/ARHP Annual Meeting
Prevalence and Associations of Hepatitis C Arthritis in Chronic Hepatitis C Virus Infection
Elizabeth D. Ferucci¹, Holly S. Ryan², Tammy L. Choromanski¹, Lisa J. Townshend-Bulson², Stephen E. Livingston², Brian J. McMahon² and Mark H. Wener³, ¹Division of Community Health Services, Alaska Native Tribal Health Consortium, Anchorage, AK, ²Alaska Native Tribal Health Consortium, Anchorage, AK, ³Rheumatology & Lab Med, University of Washington, Seattle, WA
Background/Purpose: Chronic infection with hepatitis C virus (HCV) has been reported to cause inflammatory arthritis and/or fibromyalgia. Case series of patients with HCV-associated arthritis have…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].